Long-term reversal of diabetes by the injection of immunoprotected islets.

The intraperitoneal injection of insulin-producing islets immunoprotected by an alginate-poly(amino acid) membrane is a potential method of reversing diabetes without the need for lifelong immunosuppression. Previous attempts to demonstrate this technology in large animals have failed, preventing application in humans. We have determined that key factors responsible for these past failures include cytokine (interleukins 1 and 6 and tumor necrosis factor) stimulation by mannuronic acid monomers from alginate capsules with weak mechanical integrity, which results in fibroblast proliferation. With this insight, we formulated mechanically stable microcapsules by using alginate high in guluronic acid content and report prolonged reversal of diabetes in the spontaneous diabetic dog model by the intraperitoneal injection of encapsulated canine islet allografts. Euglycemia, independent of any exogenous insulin requirement, was noted for up to 172 days. Graft survival, evidenced by positive C-peptide release, was noted for as long as 726 days in a recipient receiving a single injection of immunoprotected islets. Histological evidence of viable islets retrieved from the peritoneal cavity 6 months posttransplant confirmed the biocompatibility and immunoprotective nature of this capsule formulation. The finding that intraperitoneal injection of alginate-immunoprotected islets, a minimally invasive surgical procedure, is effective in prolonged (> 1 year) maintenance of glycemic control, without the need for lifelong immunosuppression, may have significant implications for the future therapy of type I diabetes in humans.

[1]  J. Najarian,et al.  Effects of pancreatic transplantation on diabetic neuropathy. , 1990, The New England journal of medicine.

[2]  V. D’Agati,et al.  The role of CD4+ helper T cells in the destruction of microencapsulated islet xenografts in nod mice. , 1990, Transplantation.

[3]  R. Calafiore Transplantation of microencapsulated pancreatic human islets for therapy of diabetes mellitus. A preliminary report. , 1992, ASAIO journal.

[4]  A. Sun,et al.  Microencapsulated hepatocytes as a bioartificial liver. , 1986, ASAIO transactions.

[5]  J. Vilček,et al.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[6]  G. Skjåk‐Braek,et al.  An immunologic basis for the fibrotic reaction to implanted microcapsules. , 1991, Transplantation proceedings.

[7]  P. Libby,et al.  Inducible interleukin-1 gene expression in human vascular smooth muscle cells. , 1986, The Journal of clinical investigation.

[8]  F. Lim,et al.  Microencapsulated islets as bioartificial endocrine pancreas. , 1980, Science.

[9]  G. Skjåk‐Braek,et al.  SUCCESSFUL REVERSAL OF SPONTANEOUS DIABETES IN DOGS BY INTRAPERITONEAL MICROENCAPSULATED ISLETS , 1992, Transplantation.

[10]  Patrick Soon-Shiong,et al.  Induction of Cytokine Production from Human Monocytes Stimulated with Alginate , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[11]  R. Bilous,et al.  The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. , 1989, The New England journal of medicine.